Skip to main content
Premium Trial:

Request an Annual Quote

Interpace Thyroid Tests Covered by Four New BCBS Plans

NEW YORK (GenomeWeb) – Interpace Diagnostics said today that its ThyGenX and ThyraMir molecular thyroid tests have received coverage from four additional Blue Cross Blue Shield plans.

The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used to diagnose thyroid nodules with indeterminate cytology. According to Interpace, both tests are now covered by Blue Cross Blue Shield of Arizona, Blue Cross Blue Shield of South Carolina, Wellmark Blue Cross Blue Shield of Iowa, and Wellmark Blue Cross Blue Shield of South Dakota. The four payors represent more than 5 million members combined.

"The coverage of ThyGenX and ThyraMir by these additional Blue Cross Blue Shield plans is further evidence that we have met the clinical utility threshold required to secure reimbursement for these tests," Interpace President and CEO Jack Stover said in a statement.

Interpace said that its thyroid tests are now covered for over 280 million patients nationwide, including through Medicare, Medicare Advantage, and national and regional health plans.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.